Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm dedicated to discovering and advancing treatments for critical health issues, particularly hepatitis delta virus (HDV), among other severe diseases. The company's marketed product, Zokinvy, is prescribed for patients suffering from Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its development pipeline includes several key candidates: Lonafarnib: An orally administered farnesylation inhibitor that has successfully concluded Phase 3 clinical trials for HDV infection. Peginterferon Lambda (lambda): Currently in clinical development for HDV, this compound is also being investigated in Phase II and III investigator studies for mild to moderate COVID-19. Avexitide: This therapy is in Phase II trials for treating congenital hyperinsulinism and post-bariatric hypoglycemia. Based in Palo Alto, California, the company recently announced a significant corporate event: on April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliated entities, submitted a voluntary petition for reorganization under Chapter 11 to the U.S. Bankruptcy Court for the Northern District of Texas.